Cancer Treatments
Articles tagged with Cancer Treatments
UT MD Anderson shares latest research breakthroughs
Share proton therapy across national borders and plan five new centres in Romania, Greece, Italy, Northern Ireland and Poland to maximise access for patients in Europe
Slowly ticking breast cancer cells offer new clues to late relapse
Researchers have identified a hidden mechanism explaining why breast cancer can return years after successful treatment. Slow-growing breast cancer cells can form microscopic tumours that silently tick away in distant organs, evading detection for decades.
City of Hope researchers to share new immunotherapy and precision medicine insights across cancer types at ASCO 2026
At ASCO 2026, City of Hope experts will present research on innovative treatments for various types of cancer. Their findings include the efficacy and safety of immunotherapy combinations, as well as the potential use of CBM588 to enhance immune checkpoint blockade in metastatic renal cell carcinoma.
Nanoparticles overcome drug-resistant cancer via sequential drug release and photothermal therapy
Combination therapy with stem cell-derived immune cells boost anti-cancer response
A recent study reveals that combining iNKT cell therapy with antigen-presenting cells activated by a lipid compound triggers effective antitumor immunity. The therapy generates memory-phenotype T cells that can recognize and respond to specific threats, offering a promising personalized approach to cancer treatment.
NIH-funded study suggests that testosterone suppresses brain tumor growth in males
A NIH-funded study discovered that testosterone may play a key role in limiting brain tumor growth in men by suppressing inflammation and stress hormone production. Analysis of over 1,300 men with glioblastoma found that supplemental testosterone was significantly associated with improved survival rates.
New kind of CRISPR could treat viral infection and cancer by shredding sick cells’ DNA
A new CRISPR protein, Cas12a2, has shown potential for killing sick cells while leaving healthy ones untouched. Researchers have tested its effectiveness in destroying cancer cells and virus-infected cells with promising results.
UT MD Anderson shares latest research breakthroughs
Researchers at UT MD Anderson Cancer Center have made significant advancements in targeted therapy treatments for advanced lung cancer and early-stage classical Hodgkin lymphoma. The studies showcase high response rates with novel combination therapies and a new understanding of how an enzyme affects infertility and cancer progression.
Researchers find potential one-two punch against triple-negative breast cancer
A study published in Cell Reports Medicine found that inhibiting RNase H2 can cause significant damage to DNA and activate the innate immune system to produce signals that attract T cells to attack the tumor. This approach could lead to improved patient outcomes for patients with triple-negative breast cancer.
Trial now enrolling seeks to answer key question: Does adding chemotherapy to hormone therapy improve survival for metastatic prostate cancer?
The ASPIRE trial aims to enroll 1,200 participants with advanced prostate cancer and assess the impact of chemotherapy on overall survival and disease progression. Genetic profiling is included to identify patients who benefit most from intensified treatment.
How a mental health strategy helps young adults navigate cancer diagnosis
Researchers at Rutgers University tested the efficacy of Bright IDEAS, a problem-solving skills training intervention, in reducing depression and anxiety symptoms and improving health-related quality of life among young adults with cancer. The study found significant reductions in symptoms and improvements in quality of life compared t...
UH researchers discover potential breakthrough for Crohn’s disease treatment
Researchers from UH, Baylor College of Medicine and MD Anderson Cancer Center propose a new treatment approach for Crohn's disease by targeting the stress signal that fuels inflammation. They found that repurposing two existing cancer medications can promote natural repair and regeneration of the intestinal lining.
Researcher awarded $2.75M NIH grant to develop next-gen cancer treatments
Binghamton University Professor L. Nathan Tumey is working on developing new chemical technologies for antibody-drug-conjugates to push the boundaries of what can be accomplished in ADCs. The goal is to awaken tumor-associated immune cells and prevent cancer regrowth.
New targeted therapy shows promise against aggressive childhood and adult cancers
A new targeted therapy has shown strong results in preclinical studies against aggressive childhood and adult cancers, eliminating tumours and stopping cancer spread. The therapy targets the IL1RAP protein, which is found on cancer cells but largely absent from normal tissues, allowing for precise delivery of treatment.
Extra sets of chromosomes may help aggressive tumor cells spread, study finds
A new study from Tulane University found that extra sets of chromosomes in tumor cells make them more mobile and likely to engulf neighboring cells. This stress response triggers an abundance of proteins, reprogramming the cells for motility and phagocytosis.
AACR: Novel approach prevents cancer progression, spares surgery for majority of patients with precancerous oral lesions
A new treatment using low-dose nivolumab injections into precancerous oral lesions significantly reduced lesion size and risk of cancer progression. The study showed a 60% average reduction in lesion size and complete pathologic response in six patients, with no dose-limiting side effects.
Dr. Aditya Bardia elected to American Society for Clinical Investigation
Dr. Aditya Bardia has been elected to the American Society for Clinical Investigation for his outstanding contributions to research and patient care in breast cancer treatment. He is advancing precision medicine therapies through antibody-drug conjugates and liquid biopsy technologies.
Brown Health researchers identify key molecule behind 'exceptional responders' with glioblastoma
Researchers discovered a powerful molecule called miR-181d that weaks tumors and helps the immune system fight back against glioblastoma. The study found that tumors in 'exceptional responders' contain higher levels of miR-181d, which blocks cancer cells' ability to repair DNA damage.
Cellular neighborhoods inside tumors may predict which patients with melanoma benefit from combination immunotherapy
Researchers found that tumor genetics alone did not explain which patients responded to combination therapy, but rather the tumor's immune environment. Patients with active networks of cancer-killing T cells were more likely to benefit from treatment, while those with dense clusters of plasma cells were less likely.
Understanding the diverse chemokine signals in tumor microenvironment for advanced immunotherapy
Chemokines regulate immune cell infiltration and local immunity in tumors, and targeting their receptor axis has emerged as a promising therapeutic target in cancer immunotherapy. Chemokine-modulating strategies combining with other immunotherapies have demonstrated considerable synergistic potential.
Alliance for Clinical Trials in Oncology supports April Head and Neck Awareness Month
The Alliance for Clinical Trials in Oncology has several active trials specifically designed to help people with head and neck cancers. Trials include testing high-dose prophylactic gabapentin to prevent opioid use during treatment, as well as immunotherapy with nivolumab and cabozantinib for mucosal melanoma and nasopharyngeal carcino...
Key protein that drives the spread of aggressive breast cancer identified
A specific protein, PKC-eta, has been identified as a central driver of aggressive breast cancer cell migration and metastasis. Reducing PKC-eta activity significantly slows tumor growth and reduces metastatic spread in laboratory and animal models.
New study pinpoints barriers to timely head and neck cancer treatment in rural areas
A new study led by Dartmouth Cancer Center identifies key barriers to timely head and neck cancer treatment in rural areas, including transportation and caregiver challenges. The research highlights the importance of dedicated staff, strong community ties, and peer support in navigating the complexity of cancer care.
A molecular movie captures cancer’s great escape from targeted therapy
A new study reveals that cancer cells may begin escaping therapy much earlier, triggered by a stress response that drives them into a temporary drug-tolerant state. Researchers identified an early molecular trigger: NF-κB, which acts as a regulator of cellular stress and survival.
Large DRUP-trial sheds light on hidden potential of existing cancer drugs
A large DRUP trial reveals that existing targeted cancer therapies can deliver profound and durable benefits, even in heavily pretreated or rare cancers. About one-third of patients responded to treatment or had stable disease for at least four months.
CRISPR variant selectively targets tumor DNA
Researchers identified a CRISPR variant that distinguishes tumor DNA from healthy DNA and selectively cuts the former. This method relies on methyl groups attached to DNA, which are altered in cancer cells.
AACR: UT MD Anderson shares latest breakthroughs in cancer research
Researchers from UT MD Anderson Cancer Center present studies on single-cell technologies, integrative computational approaches, and experimental therapeutics, highlighting innovations in mRNA vaccines and spatial multi-omics techniques. The studies aim to improve immunotherapy responses and detect treatment-resistant glioma cells.
UCalgary led International study explores why multiple myeloma patients often relapse after immunotherapy
A University of Calgary-led study found that multiple myeloma tumour cells adapt in multiple ways to become resistant to treatment, highlighting the need for personalized cancer therapy. The research aims to develop next-generation treatments designed to anticipate and overcome these changes.
Targeting senescent ADSCs in adipose tissue: Tongji University team paves new way for ovarian cancer therapy
Ovarian cancer cells induce adipose tissue dysfunction and ADSC senescence, creating favorable conditions for tumor metastasis. Targeting senescent ADSCs with dasatinib plus quercetin or resveratrol achieves remarkable efficacy in delaying tumor progression and reducing metastases.
Clinical trial aims to address vaginal complaints after breast cancer diagnosis
A clinical trial aims to evaluate whether laser therapy reduces vaginal dryness caused by breast cancer treatment. The study, REVITALIZE, plans to enroll approximately 250 women with a history of breast cancer who experience moderate to severe vaginal dryness.
Germ layer specification and organotropism in lymphoma invasion
This study reveals that lymphoma cells exhibit organotropism based on their germ-layer origin, with different mutations affecting migration patterns and survival. The research provides insights into the molecular basis of tumor invasion and metastasis, offering a new perspective for personalized cancer treatment.
New insights into focal adhesion kinase reveal promising paths toward next-generation cancer therapies
A comprehensive review highlights FAK's driving role in tumor progression, immune evasion, and resistance to modern cancer therapies. Emerging strategies targeting FAK's enzymatic and scaffold functions hold promise for overcoming resistance mechanisms.
Why anti-cancer drugs do not always live up to expectations
A new study reveals that two key BET proteins, BRD2 and BRD4, perform distinct roles in gene activation. Blocking both simultaneously disrupts the process, producing unpredictable effects. Targeted therapies may be more effective if they distinguish between these roles.
Newly funded projects to develop more effective drugs with fewer side effects for hard-to-treat cancers
Antidepressant unable to prevent chemotherapy-associated nerve damage
A randomized trial found that duloxetine does not prevent painful neuropathy caused by oxaliplatin-based chemotherapy in patients with stage II or III colorectal cancer. The study suggests that duloxetine should only be used for managing existing neuropathy, not prevention.
EANM joins EMUC26 as co-organizer of Europe’s leading urological cancer congress
The European Association of Nuclear Medicine (EANM) has joined the EMUC26 congress to promote nuclear medicine expertise in urological cancers. The event will bring together healthcare professionals from various disciplines to discuss current practices and emerging innovations.
Researchers develop AI tool to predict Barrett’s esophagus recurrence after therapy
Researchers developed an AI model to predict Barrett's esophagus recurrence after endoscopic eradication therapy. The tool shows high accuracy in identifying patients at risk and detecting when recurrence is likely to occur.
Adjuvant PD-1/PD-L1 inhibitors show efficacy but highlight safety considerations in solid cancers
The study found that immune checkpoint inhibitors significantly improved key clinical outcomes, including disease-free survival and distant metastasis-free survival. However, no clear improvement in overall survival was observed across studies, highlighting the need for careful patient selection and monitoring.
American Cancer Society grant to fund research on urinary tract cancer therapies
Weill Cornell Medicine researchers will explore novel combination therapies to address the gap in treatment options for patients with advanced urinary tract cancers. The study aims to understand how inherited genetic alterations and tumor-acquired mutations cooperate to disrupt DNA repair and drive cancers of the urinary tract.
Are we seeing changes in the rates of secondary blood-related cancers that develop due to chemotherapy or radiation?
A study from Japan has revealed a gradual increase in tAML rates, especially after breast cancer treatment. The study analyzed data from the Osaka Cancer Registry and found that the annual incidence of tAML increased from 0.13 to 0.36 per 100,000 population between 1990 and 2020.
Alliance marks Adolescent and Young Adult Cancer Awareness Week
The Alliance for Clinical Trials in Oncology is enrolling adolescent and young adult cancer patients in various trials, including genetic services and treatment studies. These trials aim to address longstanding gaps in care and improve outcomes for AYAs with cancer.
Hidden threat lurks post-cure: T-MN risks in female cancer survivors
Therapy-related myeloid neoplasms (t-MN) pose a significant threat to female cancer survivors, with limited treatment options and high mortality rates. New therapies and diagnostic approaches, such as CAR-T and hypomethylating agents, offer hope for improved treatment outcomes and prevention.
NCCN 2026 Annual Conference prepares cancer care providers worldwide for healing the whole patient
The NCCN 2026 Annual Conference emphasized the need for holistic care for adolescents and young adults with cancer, highlighting unique challenges and the importance of supportive services. The conference also addressed global cancer care realities and future strategies, emphasizing the need for collaboration and investment to address ...
Common metabolic enzyme could predict cancer immunotherapy benefits — and help more patients respond
A Rutgers study found that a protein called PHGDH can predict drug response in cancer patients and improves survival rates when combined with immunotherapy. High levels of PHGDH are associated with better responses to anti-PD-1 therapy, suggesting it could be a potential biomarker.
Targeted therapy improves long-term outcomes for patients with rare mutations driving lung cancer
A phase 1/2 clinical study found that pralsetinib improved durable responses with manageable safety profiles in patients with advanced or metastatic RET fusion-positive non-small cell lung cancer. The overall response rate was 78% and median duration of response was longer in patients with the CCDC6-RET fusion gene.
Study uncovers the mechanisms behind tumour suppressor BAP1 protein, highlighting new treatment strategies for aggressive cancers
Researchers have uncovered how BAP1 functions at the molecular level and present a novel therapeutic strategy to slow cancer progression. BAP1's role in DNA repair pathways and its potential as a biomarker for personalized treatment are also explored.
Cancer treatment: Understanding risks and side effects
Researchers used machine learning methods to identify safe time windows for outpatient stem cell therapy in multiple myeloma patients. The study found that this approach can predict adverse events and enable more precise risk assessment.
Tumor DNA circulating in patients’ blood after pre-surgery treatments predicts whether breast cancer will return
A study found that tumor DNA in patients' blood can predict whether breast cancer will return, especially after neoadjuvant treatment. Patients with detectable DNA at the end of treatment were 3.5 times more likely to relapse during follow-up.
Boron neutron capture therapy: a new hope for cancer treatment
A comprehensive review of BNCT suggests it can precisely target and destroy cancer cells while sparing healthy tissue. The therapy has shown promising results in extending overall survival and improving quality of life for patients with various types of malignant tumors.
New study finds common blood pressure drug boosts cancer treatment
A new study found that the common blood pressure medication telmisartan can significantly enhance the cancer-killing activity of olaparib, potentially expanding its use to many more patients. Telmisartan made tumors more vulnerable to PARP inhibitors, even when they lacked specific DNA repair defects.
Elinzanetant reduces severity and frequency of hot flushes and night sweats, regardless of type of hormone treatment breast cancer patients receive
A new analysis shows elinzanetant effectively relieves moderate-to-severe vasomotor symptoms (VMS) associated with endocrine therapy, regardless of the type of hormone treatment. The drug reduces VMS frequency and severity by blocking a protein that triggers these symptoms.
Radiotherapy rather than surgery may help reduce risk of lymphoedema in patients with breast cancer: results from pilot study
A pilot study found that axillary radiotherapy may be as effective as surgery in killing cancer cells while reducing the risk of painful swelling. The trial compared radiotherapy to axillary lymph node dissection and found similar cancer outcomes, but lower rates of lymphoedema after radiotherapy.
Breast reconstruction using polyurethane-coated implants reduces scarring and the need for further surgery
A new study shows that polyurethane-coated breast implants are associated with lower rates of capsular contracture and the need for corrective surgery after radiotherapy. Women who received these implants had a significantly lower risk of developing scarring and needing further surgery compared to those who received standard implants.
Breast cancer recurrence remains low, even after ten years, with radiotherapy tailored to patient’s individual risk
A recent study found that breast cancer recurrence remains low even after ten years when patients receive tailored radiotherapy. The research involved 848 patients who underwent chemotherapy and surgery, and showed that radiotherapy can be reduced or eliminated in low-risk patients, leading to a significant decrease in side effects.
European project brings AI-powered cancer genome interpretation closer to the clinic
The European project CGI-Clinics brings AI-powered Cancer Genome Interpreter (CGI) closer to clinical applications, enabling reliable and scalable tumour genome interpretation in precision oncology. The platform leverages machine learning to transform complex genomic data into actionable insights.
Small shrinking organ may prove decisive for life or death
A new study from Aarhus University reveals the thymus, a small organ previously believed to cease functioning early in adult life, plays a lifelong role in the risk of cancer and cardiovascular disease. The healthier the thymus, patients respond better to immunotherapy treatment.
New alliance clinical trial aims to improve outcomes in brain tumors
A new clinical trial will investigate whether adding the oral medication vorasidenib to standard chemotherapy improves progression-free survival for people with newly-diagnosed, grade 3 IDH-mutant astrocytoma. The study aims to recruit 400 individuals with this type of brain cancer and evaluate the safety and side-effect profile of the...
The cost of survival: Women more likely to survive cancer but suffer more severe side effects
A recent study found that women have a 21% lower risk of death compared to men, but a 12% higher risk of severe side effects from cancer treatment. The research, conducted in partnership with international collaborators, analyzed data from over 20,000 cancer patients and identified sex-based differences in survival and treatment toxicity.